BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved boomrx #peptides #fda #compoundingpharmacy #clinicalmedicine #patientaccess BoomRX FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA IS REPORTEDLY EXPECTED TO LIFT RESTRICTION ON PEPTIDES NYT Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy Forward progress